

Stem Cell Reports, Volume 16

Supplemental Information

***Rbbp4* Suppresses Premature Differentiation of Embryonic Stem Cells**

Yikai Huang, Ting Su, Congcong Wang, Lixia Dong, Shuang Liu, Yaru Zhu, Kunying Hao, Yin Xia, Qing Jiang, and Jinzhong Qin

Supplemental Information

***Rbbp4* Suppresses Premature Differentiation of Embryonic Stem Cells**

**Yikai Huang, Ting Su, Congcong Wang, Lixia Dong, Shuang Liu, Yaru Zhu, Kunying Hao,
Yin Xia, Qing Jiang, Jinzhong Qin**

Supplemental Figures and Legends




Figure S1. Generation of Conditional Inactivation of *Rbbp4* in ESCs, Related to Figure 1

(A) Overview of the gene targeting strategy. The wildtype *Rbbp4* locus, *Rbbp4* gene-targeting vector, the targeted allele and the excised allele are shown. (B) Genomic PCR analysis of the targeted allele and the floxed allele. (C) RT-PCR analysis for residual *Rbbp4* mRNA revealing a shorter band by transient expression of Cre recombinase. (D) Western blot analysis using a specific antibody against RBBP4 demonstrating absence of the protein in the sample three days after transient expression of Cre. ACTIN served as a loading control.




Figure S2. Generation of *Rbbp7* Null ESCs by CRISPR-Cas9, Related to Figure 1

(A) Schematic illustration for production of *Rbbp7* knockout ESCs via CRISPR/Cas9-mediated gene targeting. The sgRNA sequences are highlighted in blue and PAM sequences are in red. Primers used for PCR and sequencing are depicted as gray arrows. (B) Direct sequencing of the PCR product from *Rbbp7*^{Δ/Δ} ESCs determining deletion of 1399bp DNA fragment. (C) Genotyping of *Rbbp7*^{Δ/Δ} ESCs using primers on the both sides of targeted region. (D) RT-PCR analysis of *Rbbp7*^{Δ/Δ} ESCs showing a shorter band in the mutant. β -actin was shown as a loading control. (E) Western blot analysis revealing the absence of RBBP7 protein in *Rbbp7*^{Δ/Δ} ESCs. ACTIN was shown as a loading control.




Figure S3. Loss of *Rbbp4* resulting in reduced levels of the phosphorylated and hyperphosphorylated forms of the Rb protein (ppRb), Related to Figures 1 and 2

(A) Western blot analysis of the phosphorylated and hyperphosphorylated forms of the Rb protein in ESCs of the indicated genotypes. (B) Western blot for P21, FOXA2 and GATA6 in *Rbbp4^{F/F}* following transfection with Cre. ACTIN was used as a loading control.




Figure S4. Schematic domain structures and function analysis of Rbbp4 and its deletion mutants, Related to Figure 3

(A) Schematic domain structures and function analysis of RBBP4 and its deletion mutants. A concise schematic diagram of known structural characteristics of wild-type RBBP4 is shown at the top of the panel. The thin broken lines represent deleted regions. Results of pluripotency rescue assays using *Rbbp4^{F/F}* ESCs reexpressing wild-type RBBP4 or deletion mutant proteins are presented on the right. +, rescue; +/-, partial rescue; -, no rescue. (B) The expression of different *Rbbp4* deletion mutant proteins in *Rbbp4* null ESCs. Protein levels of corresponding RBBP4 mutants were examined by western blotting with anti-FLAG antibody. ACTIN served as the loading control. (C) RBBP4 peaks at the indicated pluripotency-associated gene locus. (D) ChIP-qPCR analysis of RBBP4 binding to the select promoter regions in wild-type and deletion mutants. (E) Real-time PCR detecting *Klf4*, *Esx1*, and *Zic1* expression levels in indicated ESCs reexpressed wild-type and deletion mutants. Data were normalized to β -actin and values are represented as mean \pm SD, (n=3). (F) Summary of results from rescue of *Rbbp4* deletion mutants. Morphology of respective mutant ESC colony with (bottom) or without (top) AP staining. The outlines of obviously defective colonies are circled. Scale bar, 100 μ m. (G) Percentage of isolated single ESCs of the indicated genotypes giving rise to macroscopic colonies. (H) Quantitative analysis of colony formation assay in ESCs of indicated genotypes. AP-stained colonies were scored as undifferentiated (undiff.), mixed or differentiated (diff.). Data are plotted as mean \pm SD of three independent experiments in triplicates. *p < 0.05, **p < 0.01 and ***p < 0.001 (Student's t test) compared with the control.




Figure S5. Generation of Single Knockout and Combined Knockout ESC lines of PRC2 Core Subunits, Related to Figure 7

(A, B, F, G) Schematic overview of the strategy to generate *Ezh1*, *Ezh2*, *Suz12* and *Eed* knockout ESCs, respectively. PAM sequences are in red following the sgRNA sequence highlighted in green. The locations of genomic PCR primers (G-F, Forward; G-R, Reverse) are indicated by red arrows. (C, H) Genotyping of indicated knockout ESCs using primers upstream and downstream of the deleted region. (D, I) RT-PCR analysis for residual mRNAs revealing a shorter band in corresponding mutants. RT-PCR primers were represented by green arrows. *β-actin* served as a loading control. (E, J) Western blot analysis using specific antibodies recognizing related proteins demonstrating absence of the protein in knockout ESC lines. (K) Percentage of isolated single ESCs of the indicated genotypes giving rise to colonies. (L) Bar graphs summarize the mean diameter of 30 random ESC colonies of the indicated genotypes. (M) Quantitative analysis of colony formation assay in ESCs of indicated genotypes. AP-stained colonies were scored as undifferentiated (undiff.), mixed or differentiated (diff.). Data in (K) to (M) represent as mean ± SD obtained from three independent experiments, *p < 0.05, **p < 0.01 and ***p < 0.001 (Student's t test) compared with the control.




Figure S6. Generation of *Jarid2*, *Aebp2* or *Pcll-3* Knockout ESCs, Related to Figure 7

(A, B, F, G, H) The schematic of *Jarid2*, *Aebp2* and *Pcll-3* gene targeting strategies, respectively. Deleted regions are shown on the corresponding panels. The locations of genomic PCR primers (G-F, Forward; G-R, Reverse) are shown by red arrows, and RT-PCR primers (RT-F, Forward; RT-R, Reverse) are represented by green arrows. (C, I) Genomic PCR for analysis of indicated knockout ESCs. (D) RT-PCR analysis for residual *Jarid2*, *Aebp2* and *Pcll-3* mRNA. (E) The absence of the proteins JARID2 or AEBP2 in knockout ESCs analyzed by Western blot. ACTIN served as a loading control.

Supplemental Tables

Table S1. All sgRNA sequences and primer sequences for genomic PCR and RT-PCR used in this study.

SgRNAs (related to Figures. 1, 7 and S1, S2, S5 and S6)		
Gene Name	Upstream sgRNA	Downstream sgRNA
<i>Rbbp4</i>	GTGATGACTAATTGTCCTCT	GGCCCAGGTTCAATTCCCAA
<i>Rbbp7</i>	AGATGGGAAGCAGGGTTTTG	TGATAGCAGATTATACTTGC
<i>Ezh1</i>	CCAGCCCTGCAGAATTGCGA	CGTGAATCCCTTTTCGGGAGC
<i>Ezh2</i>	ATTACATATACTAGACTAGT	CAATCCAAATCCAATGTGGT
<i>Suz12</i>	GACCCCTTAGGTTTTACCTTC	TGTCTACTATGCCTAAAACC
<i>Eed</i>	CCAGCTAGGGCTACGCACCA	AAACAGTAAGAGTCGAGTCG
<i>Jarid2</i>	ACTCATCGGGCCGAGCGCT	GGGTTTCTAATTCTGCATGC
<i>Aebp2</i>	GTCAGGCTGCACACGCGCTA	TAGATTCCCGGGCTCCGCCG
<i>Phf1</i>	AAATGATCTTTGCGGAATCA	CAAGGAAGCACGGTTAAGAA
<i>Mtf2</i>	CTTTTAGGCATAAGGAACGA	CAACCCTAGTGCTCTTGA
<i>Phf19</i>	AGCCTCCTGGACTCGTAGTG	GATAATTAACGTCTACTCA
<i>Pou5f1</i>	GGATTACATGCTCGTTCGTC	TACTGGCTTTCTCCAACCGC
Primers_Genomic PCR (related to Figures. S1, S2, S5 and S6)		
Gene Name	5' Forward	5' Reverse
<i>Rbbp4</i>	GGATCCCTCAGTCTCACCAG	TCCTGCCTCATGTGCCTTAG
<i>Rbbp7</i>	AGATGGGAAGCAGGGTTTTG	TCATTGTTGAAGCTGCTGGT
<i>Ezh1</i>	CTGCTTTTGAGGACGTCTGG	TTGACTGGAGTGAGCAGAGG
<i>Ezh2</i>	GTACCCTCTCCCCTGTCC	ACACAGTGGGTTGAGGTAGG
<i>Suz12</i>	TGGCGTAAATGTGTGTGTGG	CGCGCGTGTTCATCTTTA
<i>Eed</i>	AGGGTGACACTGAATCTGCA	CTCTCTCCTGCCACCTACAC
<i>Jarid2</i>	AGTGTGCTGGGTCTTGCTT	AACCCTAAAACCCAGGATG
<i>Aebp2</i>	CTTGCTCCACTTACGGCTTC	CTTGCTCCACTTACGGCTTC
<i>Phf1</i>	GGGGCACTCAGGGAAGTTAT	TGCAGAGGGACAGACAGATG
<i>Mtf2</i>	AGTGACGCTGGGTCTTGCTT	ACACTCCAAAGTGGCAAAGG
<i>Phf19</i>	GGGGAGAGCCAGATGTGTTA	ATGGCCACTTTCATGCTTTC
Primers_RT-PCR (related to Figures. S1, S2, S5 and S6)		
Gene Name	5' Forward	5' Reverse
<i>Rbbp4</i>	GGAAGAACGGGTGATCAACG	AGGGGTTCTGAGGCATGTAC
<i>Rbbp7</i>	TTCAGTGGCCAGTCTTACC	TTGCCTTCCTTTGGTCCTG
<i>Ezh1</i>	CCATTGCGTCCATGTTTCTT	CATGGCGTACTCCTTTGCTC
<i>Ezh2</i>	AAAGACACCACCTAAACGCC	ACATGGTTAGAGGAGCCGTC
<i>Suz12</i>	AGAAGCCGAAAATGGAGCAC	TGTGGAAGAAACCGGTAAATGT
<i>Eed</i>	AGGAAGGAAAAGCTGGGGAA	CCCTTCCACACCTCCGAATA
<i>Jarid2</i>	CTTCATCTTCGTGCCAGTCA	CAGGGAGTGGAAGTTGTGGT
<i>Aebp2</i>	GACGAGGACGAGGAGGAC	CACGCTACTGCTGCTGCTAC
<i>Phf1</i>	CCTTCTGTCGACTCCTCCTG	TTACAGCAAACGCTGAGGTG
<i>Mtf2</i>	CAAGCGGTCTCCTTTACGTC	TGGTCCAGAACTGCAGACAG
<i>Phf19</i>	CAAGTGGGACCGGCTGAC	GCTGGTAGGACAGCACCATT

Table S2. All primer sequences for RT-qPCR and ChIP-qPCR used in this study.

Primers_RT-qPCR (related to Figures. 2, 4, 5, 6 and 7)		
Gene Name	5' Forward	5' Reverse
<i>Dppa5a</i>	CAGGCCATGTTTGAGCTGAA	ACTCGATACACTGGCCTAGC
<i>Fgf4</i>	TCTGCCCAACAACACTACAACG	GAGGGGTAGGGTGTGCTTC
<i>Lefty1</i>	CGCACTGCCCTTATCGATTC	ACTTGTGTGAGCTCCAGGTT
<i>Nanog</i>	ATGCGGACTGTGTTCTCTCA	CCGCTTGCACCTTCATCCTTT
<i>Utf1</i>	AGACTCTGCCTACTTACCGC	TCTGGTTATCGAAGGGTCCG
<i>Foxd3</i>	CGAGTTCATCAGCAACCGTT	GGTCCAGGGTCCAGTAGTTG
<i>Tcl1</i>	TTTCCTCTACACTGGGCTCC	GAGGAGGTGAGGAGAACTGG
<i>Sox2</i>	CGCGGAGTGGAACCTTTTGT	CGGGAAGCGTGTACTTATCC
<i>Pou5f1</i>	GGATGGCATACTGTGGACCT	TCTCCAACCTCACGGCATTG
<i>Nr5a2</i>	TGAAGCAGCAGAAGAAAGCC	TGTCATAGTCTGTCCGGAGGC
<i>Sox17</i>	GCCGAGCCAAAGCGG	GTCAACGCCTTCCAAGACTTG
<i>Fgf5</i>	TTGCGACCCAGGAGCTTAAT	CTACGCCTCTTTATTGCAGC
<i>Brachyury</i>	CCAAGGACAGAGAGACGGCT	AGTAGGCATGTTCCAAGGGC
<i>Flk1</i>	GCTTGCTCCTTCCTCATCTC	CCATCAGGAAGCCACAAAGC
<i>Gata6</i>	CCCACTTCTGTGTTCCCAATTG	TTGGTCACGTGGTACAGGCG
<i>Foxa2</i>	CCCTACGCCAACATGAACTCG	GTTCTGCCGGTAGAAAGGGA
<i>Sox11</i>	AGAACATCACCAAGCAGCAG	TCCTTATCCACCAGCGACAG
<i>Nestin</i>	AGGTGTCAAGGTCCAGGATG	AAGGAAGCAGACTCAGACCC
<i>Gata4</i>	AAACCAGAAAACGGAAGCCC	ATAGTGAGATGACAGCCCGG
<i>Msx2</i>	CCTATCAACTCACCCCTGCA	CATTCAGGAGCAGAGTTGGC
<i>Hand1</i>	CAGCTACGCACATCATCACC	GAAATCTGGGGCAGCATCAG
<i>Gata2</i>	GATGAATGGACAGAACCGGC	TTCTTCATGGTCAGTGGCCT
<i>Ets2</i>	GGCACCAAACACTACCCAAAG	GTCGTGGTCCTTGGGTTTTTC
<i>Cdx2</i>	GAAACCTGTGCGAGTGGATG	CAGCCAGCTCACTTTTCCTC
<i>Cyp11a1</i>	CGAGTTCACAGGCTGCATAC	ACTCCGCTAACCACACAGAA
<i>Gata3</i>	CCCTTCTCCAAGACGTCCAT	CTTTCTCATCTTGCCTGGCC
<i>Actin</i>	AGCCATGTACGTAGCCATCC	CTCTCAGCTGTGGTGGTGAA
<i>Hprt1</i>	GAATCCTCTGGGAGACGACA	CGGAAAGCAGTGAGGTAAGC
<i>Gadd45g</i>	AAGCACTGCACGAACCTTCTG	ACGTGAAATGGATCTGCAGC
<i>Plk2</i>	CTCCGGACAGACTCTCTTCC	CTAGGCTGCTGGGTTATCGA
<i>Creb3</i>	TGTCACCTTCCGAGAACTCC	GAACCCCTCCTTTTCGAAGC
<i>Ccnb1</i>	TTGTGTGCCCAAGAAGATGC	ACGTCAACCTCTCCGACTTT
<i>Cdkn1a</i>	GAGAAAACCCTGAAGTGCCC	GTTTGGAGACTGGGAGAGGG
<i>Klf4</i>	GACATCAATGACGTGAGCCC	TGGGCTTCCTTTGCTAACAC
<i>Esx1</i>	AAACTACCAGGAACCCGAGG	ATCAGAGGACGCATCAGGG
<i>Zic1</i>	TGAACATGGCTGCACATCAC	AGATGTGGTTGCTCTGCTCT
<i>Cdkn2b</i>	CTGCCACCCTTACCAGACC	GCAGATACCTCGCAATGTCA
<i>Ccn1</i>	ACAGACCCAAGGCTCACTAC	TCCAGGAAGTTGACAGCCAA
<i>Hmga2</i>	CAAGAGCCAACCTGTGAGC	ACGACTTGTTGTGGCCATTT

<i>Ccnd1</i>	ACTGACAACCTCTATCCGGCC	CGGATGGTCTGCTTGTCTC
<i>Cdc6</i>	TCCTCCTCCGCTCAAAGAAG	ATCCGGGACAGCTGTATTCA
<i>Krt18</i>	CTGGGGCCACTACTTCAAGA	ATCTACCACCTTGCGGAGTC
<i>Tbx2</i>	GCCTGGACAAGAAAGCCAAA	TGGTCAGCTTCAGTTTGTGG
<i>Bmp2</i>	CTGGGGCCACTACTTCAAGA	ATCTACCACCTTGCGGAGTC
<i>Sox7</i>	GAACACGCTGCCTGAGAAAA	AGGACGAGAAGAAGGTCTGC
<i>Pax6</i>	TCTGCAGGTATCCAACGGTT	GCAAAGATGGAAGGGCACTC
<i>Ncam1</i>	GAATCAGACGGCCATGGAAC	TGCTCTTCAGGGTCAAGGAG
<i>Hesx1</i>	TACATGCCCCAGATCTTCCC	TACTTCGACCTGGTTCTGGG
<i>Neurod1</i>	ATCAAAAAGCCCAAGAGACGG	GGGTCTTGGAGTAGCAAGGT
<i>Olig1</i>	GCAGCCACCTATCTCCTCAT	CAAGTTCAGGTCTGCATGC
<i>Olig2</i>	CTGCGCCTGAAGATCAACAG	CGTAGATCTCGCTCACCAGT
<i>Esrrb</i>	TCTCATCTTGGGCATCGTGT	AGTTTCTTGTACCTGCGCAC
<i>Zfp296</i>	ATTAGGGGCCATCATCGCTT	GCACAGCAACTTCCAAGGAC
<i>Nr0b1</i>	CTATGTGTGCGGTGAAGAGC	CCTTGAGTGTGATCAGACGC
<i>Gbx2</i>	TCCCGGCCATTTCTGCTAC	CTGGGGATCTGGTGGTGAAG
<i>Lefty2</i>	CATCGACTCTAGGCTCGTGT	CGAAACGGACCAACTTGTGT
Primers_ChIP-qPCR (related to Figures. 3, 7 and S4)		
Gene Name	5' Forward	5' Reverse
<i>Zic1</i>	CCTTCAAGCTCAACCCCAGT	GGAACAGAAAGTCCCGGGTA
<i>Esx1</i>	CTAGAGTGAGGCCCTTACCC	AGAGAGTCTGGGAAAGGGGA
<i>Klf4</i>	GAAGGGAGAAGACACTGCGT	GCACTTAAGGCCGACTCAAG
<i>Brachyury</i>	GGGTCGCTATCTGTTCTGCT	TGACCTCTCCAAAGCCTCAG
<i>Hand1</i>	CAAGATCAAGACTCTGCGCC	TTCTTACTTACCCCAGCCCG
<i>Sox17</i>	ATACGCCAGTGACGACCAG	GTTCTGCTTTGGCCCACAC
<i>Gata4</i>	GGCCCGTGTAATCTCTCTGA	CGCAAGTTTCCGAGCCTATC
<i>Cdx2</i>	ACCATCACCCGCATCATCA	CATCCACTCGCACAGGTTTC
<i>Tbx2</i>	CCTTACGGCGGGTCAGATC	CAGGGAGAAGGTGTCGGAAG
<i>Hprt1</i>	GAATCCTCTGGGAGACGACA	CGGAAAGCAGTGAGGTAAGC
<i>Pou5f1</i>	CAGACCCTTGAGTGCCTGA	AGGCCATCAGACACTAAGCA
<i>Sox2</i>	AGCTCGCAGACCTACATGAA	TGGAGTGGGAGGAAGAGGTA
<i>Nanog</i>	CGGCTCACTTCTTCTGACT	CATGTCAGTGTGATGGCGAG

Table S3. Antibodies used in this study, related to Figures 1, 5, 7 and S1-S6.

Antibodies	SOURCE	IDENTIFIER
Rabbit anti-Rbbp4	Bethyl	A301-206A-A
Rabbit anti-Oct4	Cell Signaling Technology	83932S
Mouse anti-Sox2	Cell Signaling Technology	4900s
Mouse anti-Nanog	Abcam	ab214549
Rabbit anti-Rbbp7	Cell Signaling Technology	#4522
Mouse anti-Ezh1	Santa Cruz Biotechnology	sc-398767
Rabbit anti-Ezh2	Cell Signaling Technology	5246S
Goat anti-Suz12	Santa Cruz Biotechnology	sc-46264
Sheep anti-Eed	R&D systems	AF5827
Rabbit anti-Jarid2	Cell Signaling Technology	13594S
Rabbit anti-Aebp2	Cell Signaling Technology	14129S
Rabbit anti-Foxa2	Abcam	ab108422
Rabbit anti-Gata6	Cell Signaling Technology	5851S
Rabbit anti-Cdx2	Cell Signaling Technology	12306S
Rabbit anti-Flag	Sigma-Aldrich	F1804
Rabbit anti-HA	Santa Cruz Biotechnology	sc-805
Rabbit anti-Ring1b	Proteintech	16031-1-AP
Rabbit anti-H3K27me3	Cell Signaling Technology	9733S
Rabbit anti-H2AK119ub1	Cell Signaling Technology	8240S
Rabbit anti-H3	Cell Signaling Technology	14269S
Rabbit anti-phospho-RB(Ser780)	Cell Signaling Technology	8180t
Rabbit anti-phospho-RB(Ser807/811)	Cell Signaling Technology	8516T
Rabbit anti-RB	Abcam	ab181616
Rabbit anti-p21	Cell Signaling Technology	#64016
Mouse anti-ppRB	BD Pharmingen	G3-245
Mouse anti-Actin	Proteintech	60008-1-Ig
Alex594-conjugated donkey anti-mouse IgG	Cell Signaling Technology	8809s
Alex488-conjugated donkey anti-rabbit IgG	Cell Signaling Technology	4412s
Alex488-conjugated donkey anti-mouse IgG	Cell Signaling Technology	4408s
Alex594-conjugated donkey anti-rabbit IgG	Cell Signaling Technology	8889s

Table S4. Additional datasets used in this study, related to Figures 2 and 3.

RNA-Seq Datasets		
Gene Name	SOURCE	IDENTIFIER
<i>Suz12</i>	(Pasini et al., 2007)	GSE31354
<i>Ezh2</i>	(Das et al., 2015)	GSE58414
<i>Eed</i>	(Das et al., 2015)	GSE58414
<i>Oct4</i>	(Loh et al., 2006)	GSE4189
<i>Sox2</i>	(Ding et al., 2015)	GSE66736
<i>Nanog</i>	(Loh et al., 2006)	GSE4189
ChIP-Seq Datasets		

Gene Name	SOURCE
<i>Suz12</i>	(Ben-Porath et al., 2008)
<i>Eed</i>	(Ben-Porath et al., 2008)
<i>H3K27me3</i>	(Ben-Porath et al., 2008)

Supplemental Experimental Procedures

Cell Culture

Mouse Embryonic stem cells (mESCs) were grown on 0.1% gelatin-coated culture dishes in DMEM medium supplemented with 15% fetal calf serum (Gibco) (v/v), 1,000 U/ml leukaemia inhibitory factor (LIF), 100 U/ml penicillin, 100 U/ml streptomycin (Thermo), 2 mM L-glutamine (Invitrogen), 1:100 non-essential amino acids (Invitrogen) and 0.1 mM β -mercaptoethanol (Sigma-Aldrich). HEK293FT and mouse embryonic fibroblasts (MEFs) were cultured in DMEM media containing 10% fetal calf serum (Gibco) (v/v), 100 U/ml penicillin-streptomycin (Thermo). MEFs were derived from E13.5 embryos and cultured as previously described (Qin et al., 2010). All cell lines used in this study were maintained in a humidified incubator at 37 °C and 5% CO₂.

Colony Formation, Alkaline Phosphatase Staining and Flowcytometry

For colony formation assay, trypsinized ESCs were seeded on mitomycin-treated feeder MEFs (about 1,000 cells per 10cm plate) and grown for 7 days before image acquisition by phase contrast microscope (Olympus TH4-200). ESC colonies were stained with Alkaline Phosphatase Detection Kit (Yeasen #40749ES60), according to the manufacturer's guidelines. After staining to reveal AP activity, the colonies were scored and the percentage of undifferentiated, mixed and differentiated colonies was calculated. (n=3; error bars indicate the mean \pm s.d.). Cell cycle analysis was performed, as previously described (Zhao et al., 2018). The experiment was carried out in strict accordance with the manufacturer's instructions (Vazyme A411-01/02). In short, $2-5 \times 10^6$ ES cells were trypsinised, washed in PBS, and then fixed dropwise into ice-cold 75% ethanol overnight at 4 °C. Whereafter, fixed cells were washed with PBS, incubated for 30 min at 37°C in precooling PBS containing 20 μ l RNase A Solution and stained with propidium iodide (PI) at 4 °C in dark for 30 min. For apoptosis analysis, Annexin V-FITC/PI apoptosis detection kit (Yeasen #40302ES60) was used. Briefly, $2-5 \times 10^5$ cells were harvested, washed and resuspended in 100 μ L binding buffer containing 5 μ l Annexin V-FITC and 10 μ l PI at room temperature in the dark for 10 min. Fluorescence intensities were acquired using a LSRFortessa flow cytometer (BD Biosciences). The data were analyzed by the ModFit LT software and FlowJo software, respectively.

Embryoid Body Formation Assay

For Embryoid body differentiation, the protocol, hanging drop assay in Qin et al. was used (Qin et al., 2012). In short, a proper number of ESCs were seeded to non-adherent Petri-dishes. Suspended drop ESCs were maintained in IMDM medium without LIF (15% fetal calf serum, 2 mM L-Glutamine, 100 U/ml Penicillin-Streptomycin, non-essential amino acids, 50 μ g/mL Ascorbic acid, 200 μ g/mL iron saturated holo-transferrin, sodium pyruvate, 450 μ M monothioglycerol, and 0.1 mM β -mercaptoethanol) to generate embryoid bodies (EBs). Three days later, the EBs were maintained on a rotating shaker using suspension culture method. The medium was replaced every 2 days throughout the differentiation

procedure. Pictures of EB morphology at day 6 and 12 were taken by Olympus (TH4-200). Total RNA was extracted (Trizol, Invitrogen) at the indicated time points and analyzed by RT-qPCR. All RT-qPCR primer sequences are available in Table S2.

Teratoma Formation Assay

5×10^6 ES cells were trypsinized, washed with PBS and injected subcutaneously into the flank of 6-week-old nude mice (the Model Animal Research Center of Nanjing University [D000521] BALB/c-*Foxn1tm*/Nju). Teratomas were surgically isolated from mice 4 weeks after injection for routine histological analysis. Firstly, for preparation of teratoma paraffin blocks, teratomas were transferred into 4% paraformaldehyde (PFA) overnight at 4 °C. Then, tissue samples were dehydrated and embedded in paraffin. Finally, 5- μ m-thick paraffin sections were deparaffinized and stained with hematoxylin and eosin (H&E) based on a standard protocol (Qin et al., 2012; Zhao et al., 2018). All paraffin-sections subjected to histological examination after H&E staining. Images were acquired with a microscope (Olympus DP73). All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of the Model Animal Research Center at Nanjing University.

Cloning and Plasmid Generation

For construction of expression vectors for *Rbbp4* with an N-terminal Flag tag, the full-length *Rbbp4* coding sequence was amplified by PCR using Phanta Max Super-Fidelity DNA Polymerase (Vazyme #P505-d1) with primers containing the Flag tag sequence (DYKDDDDK). Mutant *Rbbp4* constructs were generated by Quick-change II site-directed mutagenesis kit (Agilent). The PCR product was inserted into lentiviral vector as described previously (Qin et al., 2012). In the same way, Full-length ORFs of *Oct4*, *Sox2* and *Nanog* were amplified with primers containing C-terminal Flag-tag or HA-tag from cDNA generated from ESCs. All ORFs were subsequently inserted between the NotI and BamHI sites of lentiviral vectors by recombination using ClonExpress II One Step Cloning Kit (Vazyme #C112-01), in accordance with manufacturer's instructions. For generation of *Rbbp4* targeting vector, an ~4.3kb NotI-KpnI fragment containing ~1.3 kb upstream and ~1.6 kb downstream homology arms, FRT flanked Neo cassette, floxed exon 3 and the neomycin positive selection marker was inserted into pBS KS II vector. And all expression vectors and targeting vector were verified by sequencing to ensure no mutations were introduced in protein coding sequence.

Lentiviral Supernatant Production and Infection

Lentiviral production and delivery were performed as previously described (Qin et al., 2012). Lentiviral particles were generated by co-transfecting HEK293FT cells with the lentiviral expression vectors along with third-generation packaging plasmids using Lipofectamine 2000 (Life Technologies). Concentrated virus particles were used to infect target cells in the presence of polybrene (Sigma, final concentration of 8 μ g/ml). 24 hours after infection, ES cells were selected with puromycin (4 μ g/ml) for 3–5 days to generate stable cell lines.

Immunofluorescence

For immunofluorescence, ESCs were plated on glass slides pre-coated with poly-L-lysine solution (Sigma-Aldrich). Standard immunofluorescence staining protocols were followed. Briefly, ESCs were fixed in 4%(w/v) paraformaldehyde for 15 min at room temperature, washed with PBS and then permeabilised in 0.5% Triton X-100 in PBS for 20 min at room temperature. After three 3 min-washes

in PBS, cells were incubated for 30 min in blocking buffer (PBS, 10% (v/v) goat serum, 1% (w/v) BSA) to block nonspecific binding sites. Next, the primary antibodies were diluted to the appropriate concentration in blocking serum at 4 °C overnight. Primary antibodies used were the following: anti-SOX2 (1/200, #4900s, Cell Signaling Technology), anti-OCT4 (1/200, sc-5279, Santa Cruz Biotechnology), anti-FOXA2 (1/200, ab108422, abcam), anti-GATA6 (1/200, 5851S, Cell Signaling Technology), and anti-CDX2 (1/200, 12306S, Cell Signaling Technology). After three 3 min-washes with PBS, cells were incubated for 1h at room temperature in the dark with the secondary antibody conjugated to fluorophores (Alexa Fluor® 488 donkey Anti-Mouse IgG (H+L) Antibody, Alexa Fluor® 488 donkey Anti-Rabbit IgG (H+L) Antibody, Alexa Fluor® 594 donkey Anti-Mouse IgG (H+L) Antibody and Alexa Fluor® 594 donkey Anti-Rabbit IgG (H+L) Antibody, Cell Signaling Technology) diluted 1:1000 in PBS 1% (w/v) BSA. Subsequently, coverslips were counterstained with DAPI (4',6-diamino-2-phenylindole) (1:2000) for 5 min for nuclear detection at room temperature in the dark. After several more washes, cells were imaged with Zeiss LSM 880 laser scanning confocal microscope at 63X magnification.

Quantitative Real-time PCR

Total RNA was extracted (Trizol, Invitrogen) from cells or EBs and cDNA was generated by reverse transcription PCR using HiScript™ 1st Strand cDNA Synthesis Kit (Vazyme #R111-01) according to the manufacturer's instructions. Relative mRNA expression levels were determined by PCR using PowerUp™ SYBR® Green Master Mix (Invitrogen) on the StepOnePlus™ Real-Time PCR System (Applied Biosystems). Data were analyzed with the ddCt method, using *β-actin* as a normalizer. Detailed primer sequences for RT-PCR are provided in the Table S1.

Histone Extraction

Histone extraction was performed as previously described (Qin et al., 2012; Zhao et al., 2017). In brief, the cells were harvested, washed and resuspended in Triton Extraction buffer (TEB) (PBS containing 0.5% Triton X 100 (v/v), 2mM phenylmethylsulfonyl fluoride, 0.02% (w/v) NaN₃). Then the cells were shaken on ice for 10 min with gentle stirring and centrifuged at 6500 g for 10 min at 4 °C to spin down the nuclei. Supernatant was discarded and the nuclei pellet was washed in TEB and resuspended in 0.2 N HCL overnight at 4 °C. Then the nucleic solution was centrifuged and supernatant was collected, and neutralized HCL with 5M NaOH at 1/25 of the volume of the supernatant. Protein content was determined using the Bradford assay.

Western Blotting and Immunoprecipitations

Total protein lysates were obtained by lysing cells in RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 5 mM EDTA, and protease inhibitors) as described (Huang et al., 2018). Cell lysates were separated by SDS-PAGE and transferred to PVDF membranes. For immunoprecipitation assay, immunoprecipitations were performed as follows. Cells were harvested and resuspended in 1ml of IP lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% TritonX-100, 2 mM EDTA, Complete protease inhibitors). After a 30 min incubation on ice, anti-RBBP4 (A301-206A-A, Bethyl), anti-SUZ12 (sc-46264, Santa Cruz Biotechnology) and ANTI-FLAG® M2 Affinity Gel beads (A2220, Sigma) were added to lysates for immunoprecipitation. The lysates were incubated with rotation at 20 rpm at 4 °C overnight and centrifuged at 2000g for 5 min at 4 °C. Beads were then washed two times with IP lysis buffer and high-salt buffer (50 mM Tris-HCl pH 8.0, 450 mM NaCl, 1% TritonX-100, 2 mM EDTA, protease inhibitors),

respectively, and resuspended in 50 μ l of SDS sample buffer (125 mM Tris–HCl pH 6.8, 2% SDS, 10% glycerol, 1 mg/ml bromophenol blue, 100 mM DTT, 2% β -mercaptoethanol) and boiled at 95 $^{\circ}$ C for 5 min. Samples were loaded on SDS-PAGE for western blot analysis. Detailed antibodies used in this study are provided in the Table S3.

RNA Sample Preparation and RNA-Seq

Total RNA was extracted from ESCs using TRIzol[®] Reagent according the manufacturer's instructions (Invitrogen) and genomic DNA was removed using DNase I (TaKara). Then high-quality RNA sample was quantified using the ND-2000 (NanoDrop Technologies). RNA purification, reverse transcription, library construction and sequencing were performed at Shanghai Majorbio Bio-pharm Biotechnology Co., Ltd. (Shanghai, China), as per the manufacturer's instructions (Illumina, San Diego, CA). Shortly, 1 μ g of total RNA was prepared following TruSeq[™] RNA sample preparation Kit from Illumina (San Diego, CA) for RNA-seq transcriptome library construction. Then the library was subsequently sequenced with the Illumina Novaseq 6000. The raw sequencing data were aligned to mouse genome (Ensemble GRCm38.p5) with orientation mode using TopHat (version2.1.1) (Langmead and Salzberg, 2012). To identify differentially expressed genes (DEGs), the expression level of each transcript was calculated according to the fragments per kilobase of exon per million mapped reads (FPKM) method. RSEM (<http://deweylab.biostat.wisc.edu/rsem/>) (Li and Dewey, 2011) was used to quantify gene abundances. R statistical package software EdgeR (Empirical analysis of Digital Gene Expression in R) (Robinson et al., 2010) was utilized for differential expression analysis. RNA-seq data in this study were deposited to the Gene Expression Omnibus (accession number. GSE144155).

Chromatin Immunoprecipitation (ChIP)

ChIP was performed as described previously (Qin et al., 2012; Zhao et al., 2017). In brief, 10⁷ ES cells were collected and cross-linked for 10 min at room temperature with 1% formaldehyde (Sigma). The cross-linking reaction was terminated by the addition of glycine (0.125 M) for 5 min at room temperature followed by cell lysis (50 mM Tris pH 8.0, 1% SDS, 10 mM EDTA, protease inhibitors) at 4 $^{\circ}$ C for 20 min. Sonication was performed on a Bioruptor (Diagenode), resulting in an average DNA fragment size of 200-500 bp. Before immunoprecipitation, a 50 μ l aliquot of solubilized chromatin was transferred to a new microtube and stored at –20 $^{\circ}$ C as 'input'. The fragmented chromatin fragments were incubated overnight in dilution buffer (16.7 mM Tris pH 8.0, 0.01% SDS, 1.2 mM EDTA, 1.1% Triton X-100, 165mM NaCl, protease inhibitors) at 4 $^{\circ}$ C under rotation with the indicated antibodies ((anti-EZH2, 5246S, Cell Signaling Technology)(anti-SUZ12, ab12073, Abcam)(anti-EED, AF5827, R&D systems)(anti-RBBP4, A301-206A-A, Bethyl)(anti-H3K27me3, 9733S, Cell Signaling Technology)). After incubation, the beads coupled with immunocomplexes were then washed twice in low-salt buffer (twice) (150 mM NaCl, 20 mM Tris pH 8.0, 0.1% SDS, 1 mM EDTA, protease inhibitors), high-salt buffer (twice) (500 mM NaCl, 20 mM Tris pH 8.0, 0.1% SDS, 1 mM EDTA, protease inhibitors) and TE buffer (twice) (10 mM Tris pH 8.0, 0.25 mM EDTA, protease inhibitors). The immunocomplexes were eluted for 1h at 65 $^{\circ}$ C with 150 μ l of elution buffer (1% SDS and 100 mM NaHCO₃). Chromatin was decross-linked overnight in 0.3 M NaCl at 65 $^{\circ}$ C. The enriched DNA was treated with RNase A (0.2mg/ml) for 2 hr at 37 $^{\circ}$ C, then Proteinase K (0.2mg/ml) for 3 h at 55 $^{\circ}$ C. DNAs were then purified using DNA gel extraction kit (Axygen) for subsequent quantitative PCR or deep sequencing analyses. ChIP enrichment was analyzed by qPCR using specific primers for target genes and the data were normalized to input.

ChIP-Seq and Data Analysis

For ChIP-seq samples, cross-linking, sonication and IP were performed in *Rbbp4*^{Δ/Δ} ESCs expressing RBBP4-Flag (*Rbbp4*^{Δ/Δ}/WT) or *Rbbp4*^{F/F} ESCs expressing empty Flag vector (*Rbbp4*^{Δ/Δ}/EV) (control). Flag M2 antibody (1:1,000, catalogue number F1804, Sigma) was used in the ChIP assays. 5ng of qualified ChIP DNA were used to generate the sequencing library using a NEB kit and sequenced on the Illumina platform (HiSeq PE150). Quality filtered ChIP-seq reads were aligned to the reference genome (GRCm38/mm10) using the bowtie2 software package (version 2.1.0). Only uniquely and non-duplicate mapped reads were kept, then the reads coverage and depth were calculated by samtools. MACS2 was used to generate signal tracks files in BigWig format and normalized it to 1 million reads. The significantly enriched ChIP-seq peaks were identified by using MACS package with a P-value cutoff of 5×10^{-4} . Visualization of the mapped reads and peak calling was performed by bigwig files using IGV tools. MACS2 (version 2.1.1) was used to call peaks, and followed by peak annotation using bedtools. Differential analysis between treat and control samples was conducted using bedtools. ChIP-seq data presented in this study are accessible through GEO series accession number GEO: GSE155029.

Supplementary References

- Ben-Porath, I., Thomson, M.W., Carey, V.J., Ge, R., Bell, G.W., Regev, A., and Weinberg, R.A. (2008). An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. *Nature genetics* *40*, 499-507.
- Das, P.P., Hendrix, D.A., Apostolou, E., Buchner, A.H., Canver, M.C., Beyaz, S., Ljuboja, D., Kuintzle, R., Kim, W., Karnik, R., *et al.* (2015). PRC2 Is Required to Maintain Expression of the Maternal Gtl2-Rian-Mirg Locus by Preventing De Novo DNA Methylation in Mouse Embryonic Stem Cells. *Cell reports* *12*, 1456-1470.
- Ding, J., Huang, X., Shao, N., Zhou, H., Lee, D.F., Faiola, F., Fidalgo, M., Guallar, D., Saunders, A., Shliaha, P.V., *et al.* (2015). Tex10 Coordinates Epigenetic Control of Super-Enhancer Activity in Pluripotency and Reprogramming. *Cell stem cell* *16*, 653-668.
- Huang, Y., Zhao, W., Wang, C., Zhu, Y., Liu, M., Tong, H., Xia, Y., Jiang, Q., and Qin, J. (2018). Combinatorial Control of Recruitment of a Variant PRC1.6 Complex in Embryonic Stem Cells. *Cell Rep* *22*, 3032-3043.
- Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. *Nat Methods* *9*, 357-359.
- Li, B., and Dewey, C.N. (2011). RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC bioinformatics* *12*, 323.
- Loh, Y.H., Wu, Q., Chew, J.L., Vega, V.B., Zhang, W., Chen, X., Bourque, G., George, J., Leong, B., Liu, J., *et al.* (2006). The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. *Nature genetics* *38*, 431-440.
- Pasini, D., Bracken, A.P., Hansen, J.B., Capillo, M., and Helin, K. (2007). The polycomb group protein Suz12 is required for embryonic stem cell differentiation. *Molecular and cellular biology* *27*, 3769-3779.
- Qin, J., Van Buren, D., Huang, H.S., Zhong, L., Mostoslavsky, R., Akbarian, S., and Hock, H. (2010). Chromatin protein L3MBTL1 is dispensable for development and tumor suppression in mice. *J Biol Chem* *285*, 27767-27775.

Qin, J., Whyte, W.A., Anderssen, E., Apostolou, E., Chen, H.H., Akbarian, S., Bronson, R.T., Hochedlinger, K., Ramaswamy, S., Young, R.A., *et al.* (2012). The polycomb group protein L3mbtl2 assembles an atypical PRC1-family complex that is essential in pluripotent stem cells and early development. *Cell Stem Cell* 11, 319-332.

Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* (Oxford, England) 26, 139-140.

Zhao, W., Liu, M., Ji, H., Zhu, Y., Wang, C., Huang, Y., Ma, X., Xing, G., Xia, Y., Jiang, Q., *et al.* (2018). The polycomb group protein Yaf2 regulates the pluripotency of embryonic stem cells in a phosphorylation-dependent manner. *The Journal of biological chemistry* 293, 12793-12804.

Zhao, W., Tong, H., Huang, Y., Yan, Y., Teng, H., Xia, Y., Jiang, Q., and Qin, J. (2017). Essential Role for Polycomb Group Protein Pcgf6 in Embryonic Stem Cell Maintenance and a Noncanonical Polycomb Repressive Complex 1 (PRC1) Integrity. *J Biol Chem* 292, 2773-2784.